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Background: Nutritional support is an essential part of the management of critically ill patients. However, optimal
caloric intake has not been systematically evaluated. We aim to compare two strategies of enteral feeding:
permissive underfeeding versus target feeding.
Method/Design: This is an international multi-center randomized controlled trial in critically ill medical- surgical
adult patients. Using a centralized allocation, 862 patients will be randomized to permissive underfeeding or target
feeding. Patients in the permissive group receive 50% (acceptable range is 40% to 60%) of the calculated caloric
requirement, while those in the targeted group receive 100% (acceptable range 70% to 100%) of the calculated
caloric requirement. The primary outcome is 90-day all-cause mortality. Secondary outcomes include ICU and
hospital mortality, 28-day, and 180-day mortality as well as health care-associated infections, organ failure, and
length of stay in the ICU and hospital. The trial has 80% power to detect an 8% absolute reduction in 90-day
mortality assuming a baseline risk of death of 25% at an alpha level of 0.05.
Discussion: Patient recruitment started in November 2009 and is currently active in five centers. The Data
Monitoring Committee advised continuation of the trial after the first interim analysis. The study is expected to
finish by November 2013.
Trial registration: Current Controlled Trials ISRCTN68144998
Keywords: Enteral nutrition, Intensive Care Units, Caloric restriction, Infections, Insulin, MortalityBackground
Nutritional support is an essential part of the manage-
ment of critically ill patients [1]. Although clinical trials
have resolved the ‘when to start feeding’ question [1],
which is within 24 to 48 hours after admission to the
ICU, there is little evidence to answer the ‘how much’
question. During critical illness, the metabolic rate is
increased and complex fuel alterations occur. Fuel
choice is altered from predominantly fat to glucose* Correspondence: yaseenarabi@yahoo.com
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reproduction in any medium, provided the oroxidation, thus glycolysis increases enormously. Prote-
olysis and lipolysis are also augmented [2]. In a healthy
person, exogenously supplied calories from fat or carbo-
hydrate will suppress lipolysis and proteolysis [2]. How-
ever, this suppression is blunted by acute inflammatory
illness [2]. In fact, excess caloric provision is increasingly
perceived as having detrimental effects, particularly on
mitochondria [3], since it leads to increased oxygen rad-
ical production in addition to wasting fuel [3].
In 1997, a review concluded that there was insufficient
data from methodologically sound studies to permit firm
recommendations about the optimal amount of nutri-
tional support for critically ill patients [4]. Likewise, thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that whereas early enteral nutrition was recommended
in critically ill patients, there were insufficient data to
make recommendations on the dose of enteral feeding
except for head-injured patients [5]. Even in head injury
patients, the recommendations for optimizing delivery of
nutrients were based on only one randomized controlled
trial(RCT) [5].
The optimal caloric intake in the critically ill remains
controversial. This controversy has been heightened with
recent evidence suggesting harm and other studies sug-
gesting benefit with the use of lower caloric intake in the
critically ill. In a single-center RCT of 82 head-injured
patients, the effect of ‘early-enhanced’ enteral nutrition
(59.2% of caloric goal) was compared with standard nu-
trition (36.8% of caloric goal). At three months, the
enhanced nutrition group had a trend towards better
neurological outcome in comparison to the standard nu-
trition group and fewer overall complications, including
infections [6]. However, there were no differences in
neurological outcome at six months or in mortality [6].
The multicenter cluster-randomized Algorithms for Crit-
ical Care Enteral and Parenteral Therapy (ACCEPT) trial
investigated the impact of implementing evidence-based
feeding algorithms on nutrition practices and patient
outcomes in the ICU [7]. Patients in the intervention
group received more calories per day than those in the
control group (1,264 kcal versus 998 kcal, P = 0.31) and
had a significantly shorter hospital length of stay (LOS)
with a trend towards reduced mortality. Rubinson et al.
showed that very low caloric intake (<25% of the aver-
age daily recommended calories) was associated with an
increased risk of health care-associated bloodstream infec-
tions [8]. A single-center RCT of 28 patients showed that
lower energy deficits were associated with a decreased
need for renal replacement therapy [9].
There is also evidence to support outcome benefit with
lower than standard targeted feeding goals. In a cohort
study, Krishnan et al. found that moderate caloric intake
(33% to 65% of the recommended American College of
Chest Physicians (ACCP) targets) was associated with
better clinical outcomes including reduced mechanical
ventilation duration, ICU LOS, as well as hospital mor-
tality, when compared with higher caloric intake [10].
However, this study did not adjust for glucose control
that has been found to influence outcomes in ICU
patients. Dickerson et al. studied 40 critically ill, obese
patients and found that patients who received fewer cal-
ories (<20 kcal/kg versus ≥20 kcal/kg) had decreased
ICU LOS (P <0.03), reduced duration of antibiotic ther-
apy (P <0.03), and a trend towards decreased mechanical
ventilation duration (P = 0.09) [11]. In a single-center
quasi-RCT, 150 mechanically ventilated medical patients
were administered ‘early aggressive’ feeding or ‘late’feeding [12]. The late group received fewer calories
(629 ± 575 kcal versus 2,370 ± 2,000 kcal, P <0.001) and
had a lower incidence of ventilator-associated pneumo-
nia (30.7% versus 49.3%, P = 0.02), less Clostridium diffi-
cile induced diarrhea (4.0% versus 13.3%, P = 0.04), as
well as shorter ICU LOS (9.8 ± 7.4 versus13.6 ± 14.2
days, P = 0.04) and hospital LOS (16.7 ±12.5 days versus
22.9 ± 19.7 days, P = 0.02) compared with the early feed-
ing group [12]. An RCT with 200 mechanically venti-
lated patients and a second RCT with 1,000 patients
with acute lung injury showed that a strategy of initial
trophic enteral feeding (10 mL/hour) compared with
standard targeted enteral feeding goals for up to six days
reduced gastrointestinal tolerance, but did not improve
ventilator-free days or 60-day mortality [13,14]. The
intervention arms of these two RCTs instituted very low
trophic feeding in critically ill patients with acute lung
injury. In contrast, an RCT of 240 general medical-
surgical mechanically ventilated patients conducted by
our investigative team compared the efficacy of a moder-
ate hypo caloric (60% to 70% of calculated caloric re-
quirement) versus a eucaloric (90% to 100%) diet [15].
The endpoints of ICU, 28-day and 90-day mortality were
not statistically different (17.5%, versus 21.7%, P = 0.42;
18.3% versus 23.3%, P = 0.34 and 31.0% versus 39.3%,
P = 0.19, respectively) [15]. However, hospital mortality
was reduced in the hypo caloric diet group (30% versus
42.5%, P = 0.04), and there was a trend towards shorter
ICU LOS [15]. In contrast to very low caloric or trophic
enteral feeding, it remains unclear whether a moderate
caloric intake may improve survival and reduce
morbidity.
Rationale for the study
There is a lack of conclusive evidence regarding the cal-
oric intake dose required for enteral feeding in critically
ill patients. The available literature reports mainly on
observational studies that do not provide the best evi-
dence and existing RCTs are either conducted on spe-
cific patient populations or are not conclusive. The
objective of our Permissive Underfeeding versus Target
Enteral Feeding in Adult Critically Ill Patients (PermiT)
trial is to assess the effect of permissive underfeeding
versus target feeding on 90-day mortality in adult,
medical-surgical critically ill patients.
Methods/design
Study population, inclusion and exclusion criteria
All patients admitted to the participating ICUs are
screened daily for study eligibility. Patients are deemed
eligible for this study if they are ≥18-year old, receiving
enteral feeding, and expected to remain in ICU ≥72
hours (Time Zero would be the time of ICU admission).
Exclusion criteria are: lack of commitment to ongoing
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expected six month mortality >50%, enteral feeding not
started within 48 hours of ICU admission, parenteral nu-
trition (PN), oral feeding, previous enrollment in this
study within the same hospital admission, pregnancy,
post liver transplantation, post cardiac arrest, burns,
prisoners, and receipt of vasopressors (except dobuta-
mine) at the following doses: norepinephrine >0.4 μg/
kg/min, epinephrine >0.4 μg/kg/min, dopamine >20 μg/
kg/min, phenylephrine >300 μg/min, vasopressin >0.04
unit/min or half of these doses for patients receiving two
or more vasopressors. Patients who are initially ineligible
are reassessed multiple times for eligibility within the
randomization window of 48 hours.
Eligible patients are not randomized (eligible non-ran-
domized) if their substitute decision makers decline con-
sent, the research team is unable to get consent within
48 hours of eligibility, the treating ICU physician does
not agree with the patient being enrolled in the study or
if the patient is already enrolled in a trial of a similar na-
ture or outcome.
Randomization
PermiT is a multicenter open-label international RCT.
The patients who meet all inclusion with no exclusion
criteria are randomized into one of the two intervention
arms: the permissive underfeeding group or target feeding
group. Randomization is based on computer-generated
random permuted blocks of four and is stratified by cen-
ter and follows a concealed process using sealed and
numbered envelopes that allocate the patient to either of
the two arms of the study.
Patients may be randomized into PermiT only once
unless they were discharged from the hospital and were
re-admitted beyond 180 days of the first enrollment. The
study does not allow cross-overs and if any occur, they
will be reported as protocol violations.
Informed consent
The research coordinator and/or physician investigator
explains the objectives of this study and its potential
risks and benefits to the patient when possible or more
commonly to his/her surrogate decision maker. Once
the patient or his/her surrogate decision maker agrees, a
witnessed written consent is obtained. The patient or
surrogate can withdraw from the study at any time with-
out impact on treatment. A screening log indicating why
eligible patients were not randomized is recorded at
each of the participating centers and reported back to
the coordinating center on a three-month basis.
Trial interventions and nutrition related co-interventions
Patients in the permissive underfeeding group receive
50% of the calculated caloric requirement (with anacceptable range of 40% to 60%) and those in the target
feeding group receive100% of the calculated caloric re-
quirement (with an acceptable range of 70% to 100%).
These targets were selected to maintain moderate caloric
intake in the permissive underfeeding group yet to
achieve a larger separation in caloric intake between the
two groups compared to our previous trial [15]. Partici-
pating centers may use their own standard feeding pro-
tocols to achieve the caloric intake for both arms of the
study. The coordinating center uses a feeding protocol
that has been published earlier [16]. Head of bed eleva-
tion, minimizing discontinuation of enteral feeding dur-
ing diagnostic tests, nursing care or routine bedside
procedures are followed according to the most current
Society of Critical Care Medicine (SCCM) and American
Society for Parenteral and Enteral Nutrition (ASPEN)
clinical practice guidelines [17]. After radiographic con-
firmation of tube placement (gastric or post-pyloric),
feeding is started at 30 ml/hour and advanced by 10 ml/
hour every four hours. To achieve the prescribed enteral
feeding, daily targets are used in addition to the hourly
rate [18]. The protocol does not provide recommenda-
tions for the type of feeding tube (large-bore or small-
bore nasogastric tube with or without guide wire). For
patients fed with gastric tubes, the residuals are checked
every four hours, and for post-pyloric tubes only if there
are signs of feeding intolerance such as vomiting, ab-
dominal distention or ileus. For small size tubes that do
not permit aspiration, a second larger size tube may be
placed into the stomach to aspirate the gastric residual.
The protocol provides instructions on the management
of residuals greater than 200 ml. Prokinetic agents and
post-pyloric tubes for feeding intolerance are used at the
discretion of the treating physicians. The decision to
introduce PN is also at the discretion of the treating
team. Our PermiT study recommends following the
SCCM/ASPEN clinical practice guidelines, which con-
siders PN for both the targeted and permissive under-
feeding groups if caloric requirements are not met after
7 to 10 days by enteral route alone [17].
Enteral formulations
The type of enteral formulations used is not directed by
the study protocol and is left to the combined decision
of the treating physician and the clinical dietitian as long
as caloric targets are met. The types of formulae are
classified into non-specialized (Ensure, Ensure Plus, Jev-
ity (1.0 to 1.2), Osmolite, Resourse and Resourse Plus
(from Nestle, Novartis and Abbott, Laboratories,) or
specialized (Nepro, Pulmocare, Renal Nova Source, Glu-
cerna, Nutren Hepatic, Suplena, Vivonex Plus and Pep-
tamen (1.0, 1.2, and 1.5), and Promote (from Nestle,
Novartis and Abbott Laboratories)). Beneprotein for-
mula (from Novartis) is used to supplement protein. The
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immune modulating formulations is left to the discretion
of participating centers. Suggestions on selection of en-
teral formulations depending on patients’ health status
are outlined in Table 1 and consistent with the SCCM/
ASPEN clinical practice guidelines [17].Calculation of caloric requirements
The caloric requirement is calculated by the clinical
dietitian on study day 1 and then recalculated on study
day 7 ± 1 using different predictive equations [see
Additional file 1, Appendix A] depending on body mass
index (BMI) and whether the patient is breathing spon-
taneously or is mechanically ventilated [19-22]. The
Penn State Equation is used for mechanically ventilated
patients with BMI <30, and the Ireton-Jones, 1992 Equa-
tion is used for mechanically ventilated patients with
BMI ≥30 and for spontaneously breathing patients.Calculation of protein requirement
Both study groups receive their daily protein require-
ments. Protein requirements are based on nutritional
status, degree of stress of disease or injury and physio-
logical capability to metabolize protein. For the metabol-
ically stressed patient, current SCCM/ASPEN clinicalTable 1 Guidelines for selection of enteral feeding
formulation
Diagnostic category Enteral feeding formulation
Major elective surgery, trauma,
burns, headand neck cancer,
and critically ill patients on
mechanical ventilation




nucleic acid, omega-3 fatty acids,
and antioxidants). Grade A




by an anti-inflammatory lipid
profile (that is, omega-3 fish oils,
borage oil) and antioxidants
(grade A).
All critically ill patients receiving
specialized nutrition therapy
Antioxidant vitamins
(including vitamins E and
ascorbic acid)





Enteral glutamine to an
enteral nutrition regimen.





Renal failure Standard enteral formulations
and standard ICU
recommendations for protein
and calorie.practice guidelines recommend 1.2 to 1.5 g of protein/
kg/day [17,23].
Blood glucose management
In both groups, the target blood glucose level is 4.4 to
10 mmol/L (80 to 180 mg/dL). Study centers may use
their own insulin therapy protocols to achieve this blood
glucose target.
Other co-interventions
The use of propofol for sedation, which adds to the cal-
oric intake, is administered according to the treating
team. Each 1 ml of propofol (propofol 1% or 2% Frese-
nius) provides 1.1 Kcal. To reduce the caloric intake
from propofol, the following are recommended:
1) minimize the use of propofol; 2) use propofol for
short term sedation (up to 72 hours) as per SCCM
guidelines [17]; and 3) limit caloric intake from propofol
to ≤500 kcal/day for patients who weigh >70 kg and
≤300 kcal/day for patients who weigh ≤70 kg. The use of
dextrose-containing fluids is according to the treating
team and the insulin protocol. However, the caloric con-
tribution of dextrose and propofol is accounted for by
adjusting the enteral nutrition caloric intake on a daily
basis by the study team.
To account for the volume difference between the two
groups, patients in the permissive underfeeding receive 2
mL/kg of normal saline or water every four hours (based
on an estimated difference in the administered volume
of 30 to 40 ml/hour between the two intervention
groups) by the same enteral route unless otherwise spe-
cified by the physician. All receive multivitamins (includ-
ing vitamin E, vitamin C) and trace elements (selenium,
zinc and copper) on a daily basis. All other co-
interventions are left to the discretion of the treating
team.
Duration of the intervention
The allocated intervention is continued until any of the
following criteria is met: 1) a maximum of 14 days on
the study feeding protocol; 2) ICU discharge; 3) ICU
mortality or decision to withhold feeds as a part of a pal-
liative care plan; or 4) oral feeding started and tolerated
for >24 hours.
Data collection, frequency and duration of follow-up
following recruitment
At baseline for all randomized patients, data obtained in-
clude demographics, presence of co-morbidities such as
chronic health problems, medication use prior to admis-
sion, Acute Physiology and Chronic Health Evaluation
Scores (APACHE) II [24] and III [25] and presence of
sepsis upon admission. Nutritional data (total calories
and total protein), laboratory data (morning blood
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potassium, magnesium and phosphorous), fluid input–
output and stool frequency are recorded on a daily basis
until a maximum of 14 days of ICU stay, ICU discharge
or ICU mortality, whichever comes first. Data about
healthcare-associated infections are also collected until
two days after ICU discharge.
Outcome measures
The primary outcome is 90-day all-cause mortality.
Secondary outcomes include ICU, hospital, 28-day and
180-day mortality rates and Sequential Organ Failure
Assessment (SOFA) scores (on days 1, 3, 7, 14, 21
and 28). Tertiary outcomes include ICU and hospital LOS,
hypoglycemia, hypokalemia, hypophosphatemia, hypomag-
nesemia, health care-associated infections [26], refeeding
syndrome [27], and diarrhea [28]. Definitions of different
outcomes are outlined in Additional file 1: Appendix B.
Hospital mortality is censored at one year from the date of
enrollment. Vital status at day 90 and day 180 are recorded
if needed by telephone interview with the patient or his/
her surrogate decision maker.
Administrative and ethical aspects
The study sponsor is KAIMRC. The coordinating study
center is the Intensive Care Department at King Saud
bin Abdulaziz University for Health Sciences
(KSAUHS)/King Abdullah International Medical Re-
search Center (KAIMRC) in Riyadh, Saudi Arabia. Par-
ticipating centers include the Ottawa Hospital (General
and Civic campuses), Ottawa, Canada; Mount Sinai
Hospital, Toronto, Canada; and King Faisal Specialist
Hospital and Research Center, Riyadh, Saudi Arabia.
The study is being conducted in accordance with the
International Conference on Harmonization-Good Clin-
ical Practice (ICH-GCP) guidelines. The study protocol
and the informed consent have been approved by the
KSAUHS/KAIMRC Institutional Review Board (IRB)
(approval number IRBC/109/10) followed by the respect-
ive IRBs of all the participating centers.
Several measures are taken to ensure optimal compli-
ance with the study protocols. Before launching the
study, ICU physicians, nurses and dietitians attended
training sessions with special emphasis on adjustment of
feeding to achieve the target caloric intake. The Steering
Committee (YMA, SHH, ASA, HMD, and HMT) is re-
sponsible for overall management of the study including
providing central guidance to support participating cen-
ters for protocol adherence, addressing challenges with
protocol implementation, formulating the analysis plan,
reviewing and interpreting data and preparing the manu-
script. The average caloric intake is compared between
the two groups on a regular basis every two months and
is stratified by center. Feedback is provided to eachcenter to further improve adherence to caloric targets, if
needed. The sponsor has appointed an independent
monitor who ensures that the trial is conducted in ac-
cordance with the ethical principles of the Declaration
of Helsinki and the ICH-GCP guidelines. The monitor
has direct access to case report forms, the source docu-
ment and the trial master file at the coordinating study
center. The study also has an independent Data Moni-
toring Committee (DMC) which is responsible for over-
seeing the safety of study patients, monitoring efficacy
and protocol adherence and making recommendations
to continue or terminate the study based on safety ana-
lysis results. The DMC is composed of three members
who are not involved in the planning or execution of the
study.Analytical plan
Sample size
In our recent RCT [15], we observed an absolute risk re-
duction in hospital mortality of 8% (95% CI 0.4% to
25%). Based on an estimated 90-day mortality of 25%
and using a power of 80% and an alpha of 0.05, the sam-
ple required to demonstrate a decrease in mortality of
8% was 431 in each group (a total of 862 patients). The
flow of patients through the study will be displayed in a
‘CONSORT’ diagram (Figure 1).Statistical and analytical plan
Patients will be analyzed according to the intention-to-
treat principle, that is, all randomized patients will be
analyzed in the groups to which they were originally
allocated. Baseline characteristics will be summarized by
carrying out univariate analyses. Categorical variables
will be presented as numbers and percents, whereas the
continuous variables will be presented as mean and
standard deviations. The primary and secondary out-
comes between the two intervention groups will be com-
pared using the Chi-square test. The relative risk
reduction, absolute risk reduction and the number
needed to treat with the permissive underfeeding diet to
prevent one death will be calculated. Moreover, the
mechanical ventilation duration and ICU and hospital
LOS in the two arms will be compared using the inde-
pendent Student’s t-test. For binary outcomes, logistic
multivariate regression will be used to test the interven-
tion effect, controlling for covariates when appropriate,
such as when analyzing subgroups. Adjusted relative
risks and associated 95% CIs will be estimated using Cox
proportional hazards regression modeling. Primary out-
come will also be analyzed using survival analysis. All
tests of significance will be at the 5% significance level,
and two-sided. Analyses will be conducted using SAS
version 9.2 and/or SPSS.
Figure 1 Flow diagram.
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The following are a priori subgroups that will be ana-
lyzed: non-operative and operative patients, diabetic and
non-diabetic patients, APACHE II ≤18 and >18, specific
admission diagnoses (sepsis and traumatic brain injury),
patients on vasopressors at baseline and those who are
not and inclusion blood glucose (categorized according
to the median value).Monitoring for safety
Several measures are taken to minimize, observe and
document any potential safety concerns. First, serious
adverse events (SAEs) will be reported immediately to
the Steering Committee, IRB and DMC. Second, an in-
dependent DMC will be monitoring the safety of the
trial. Third, one interim analysis has been conducted,
and the next one will be done once 2/3 of the total sam-
ple size is recruited. Finally, site visits to the participat-
ing centers by the principal investigator or designee are
planned for data monitoring including data verification
and review of the consent process.Discussion and Trial status
This trial was designed in 2008. The protocol passed
through multiple amendments. Final approval from
IRB was obtained on 8 April 2009. The study began
enrolling at the principal site in November 2009. It
was subsequently joined by one national (King Faisal
Specialist Hospital and Research Center) and three
international centers (Ottawa Hospital, General Cam-
pus, the Ottawa Hospital, Civic Campus and Mount
Sinai Hospital in Toronto). The expected duration of
the study is four years. The first DMC meeting was
held on 7 October 2009 and a follow-up meeting on 9
February 2011. The study monitor visited the coordin-
ating site on 7 January 2012 and submitted a detailed
report to the sponsor. The first interim analysis was
carried out in March 2012 as soon as 287 patients
(one-third of the sample size) were completed with
90-day outcome. Unblinded results were submitted to
the DMC, who indicated that trial recruitment should
proceed. The results were maintained blinded to the
investigators/research team with the exception of the
biostatistician.
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